Registry, Oct 31, 2029
Dosing n/r
alkylating chemotherapy · Alliance
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
IDH-mutant glioma
Programs by company or class, across phase, filing, approval, and a stop.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
Phase 1 included.
Clear filters15 of 15 programs on this matrix
| Phase 1 | Phase 2 | Phase 3 | Filed | Approved | Discontinued | |
|---|---|---|---|---|---|---|
| alkylating chemotherapy2 programs | Registry, Oct 31, 2029 Dosing n/r alkylating chemotherapy · Alliance Registry, Dec 31, 2026 Dosing n/r alkylating chemotherapy · ECOG-ACRIN | |||||
| ATR inhibitor (ATRX-altered)1 program | Registry, Sep 2028 Dosing n/r ATR inhibitor (ATRX-altered) · GEINO | |||||
| DNMT inhibitor1 program | Registry, Jan 2027 Dosing n/r DNMT inhibitor · Massachusetts General Hospital | |||||
| mutant IDH1 inhibitor3 programs | Phase 1 once daily, oral mutant IDH1 inhibitor · Servier | Registry, Jun 2029 twice daily, oral mutant IDH1 inhibitor · Rigel | Registry, Dec 2028 twice daily, oral mutant IDH1 inhibitor · Nuvation Bio | |||
| mutant IDH1/IDH2 inhibitor2 programs | Registry, Dec 2026 once daily, oral mutant IDH1/IDH2 inhibitor · Hutchmed | SNO 2026: INDIGO 41.6-month, seizure/QoL, real-world grade 2 and 3, Nov 12, 2026 once daily, oral mutant IDH1/IDH2 inhibitor · Servier | ||||
| PARP inhibitor3 programs | Phase 1 Dosing n/r PARP inhibitor · University of California, San Francisco Phase 1 Dosing n/r PARP inhibitor · Massachusetts General Hospital | Registry, Jan 2027 twice daily, oral PARP inhibitor · Hospices Civils de Lyon (OLAGLI) | ||||
| PD-1 antibody1 program | Phase 2 Dosing n/r PD-1 antibody · National Cancer Institute | |||||
| peptide vaccine1 program | Registry, Dec 31, 2032 subcutaneous peptide vaccine · German Cancer Research Center | |||||
| retinoid plus PD-1 antibody1 program | Registry, Jun 2027 Dosing n/r retinoid plus PD-1 antibody · University of Pennsylvania (Stephen Bagley) |